Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Tycho, Bismeijer"'
Autor:
Max A.A. Ragusi, Tycho Bismeijer, Bas H.M. van der Velden, Claudette E. Loo, Sander Canisius, Jelle Wesseling, Lodewyk F.A. Wessels, Sjoerd G. Elias, Kenneth G.A. Gilhuijs
Publikováno v:
Breast, Vol 60, Iss , Pp 230-237 (2021)
Purpose: To assess whether contralateral parenchymal enhancement (CPE) on MRI is associated with gene expression pathways in ER+/HER2-breast cancer, and if so, whether such pathways are related to survival. Methods: Preoperative breast MRIs were anal
Externí odkaz:
https://doaj.org/article/a7a1e711194c46f9bfc41983bd3be40b
Autor:
Mathilde M. M. Almekinders, Michael Schaapveld, Bram Thijssen, Lindy L. Visser, Tycho Bismeijer, Joyce Sanders, Edoardo Isnaldi, Ingrid Hofland, Marjolijn Mertz, Lodewyk F. A. Wessels, Annegien Broeks, Erik Hooijberg, Wilbert Zwart, Esther H. Lips, Grand Challenge PRECISION Consortium, Christine Desmedt, Jelle Wesseling
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need
Externí odkaz:
https://doaj.org/article/0a52b05e321f481ea6b0d325da202d72
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Integrative analyses that link molecular data to treatment sensitivity are essential for precision medicine. Here the authors introduce WON-PARAFAC to integrate multiple genomics data to identify sparse and interpretable factors.
Externí odkaz:
https://doaj.org/article/2d768969dca140ab86ef9a6db53fb9f6
Autor:
Tesa M. Severson, Denise M. Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C. Schouten, Suet-Feung Chin, Ian J. Majewski, Magali Michaut, Astrid Bosma, Bernard Pereira, Tycho Bismeijer, Lodewyk Wessels, Carlos Caldas, René Bernards, Iris M. Simon, Annuska M. Glas, Sabine Linn, Laura van ‘t Veer
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-9 (2017)
Abstract Background Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between BRCA1-like and non-BRCA1-like tumors. We hypothe
Externí odkaz:
https://doaj.org/article/f9d39320e8404ffdb7196315ea5646b3
Autor:
Kenneth G.A. Gilhuijs, Lodewyk F.A. Wessels, Max A. Viergever, Claudette E. Loo, Tycho Bismeijer, Sjoerd G. Elias, Bas H.M. van der Velden
Purpose: To determine whether markers of healthy breast stroma are able to select a subgroup of patients at low risk of death or metastasis from patients considered at high risk according to routine markers of the tumor.Experimental Design: Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284466bcf6f97fbb91c584e2eddc9c93
https://doi.org/10.1158/1078-0432.c.6526788.v1
https://doi.org/10.1158/1078-0432.c.6526788.v1
Autor:
Kenneth G.A. Gilhuijs, Lodewyk F.A. Wessels, Max A. Viergever, Claudette E. Loo, Tycho Bismeijer, Sjoerd G. Elias, Bas H.M. van der Velden
Competing risk analysis; Cox proportional hazards models are shown for overall survival, breast�cancer related death, and non�breast cancer related death. For each model, pooled hazard ratios (HR) and 95% confidence intervals (CI) are s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c401d7135db1404a9f6e7ecda3cfca
https://doi.org/10.1158/1078-0432.22467927
https://doi.org/10.1158/1078-0432.22467927
Publikováno v:
PLoS Computational Biology, Vol 14, Iss 10, p e1006520 (2018)
Effective cancer treatment is crucially dependent on the identification of the biological processes that drive a tumor. However, multiple processes may be active simultaneously in a tumor. Clustering is inherently unsuitable to this task as it assign
Externí odkaz:
https://doaj.org/article/17346b17f3b14de99c5718e9369f7e74
Autor:
Mathilde Matthea Machteld Almekinders, Edwin Roger Parra, Tapsi Kumar, Karin De Visser, Tycho Bismeijer, Baohua Sun
Publikováno v:
British Journal of Cancer, 127(7), 1201-1213. Nature Publishing Group
Grand Challenge PRECISION consortium 2022, ' Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk ', British Journal of Cancer, vol. 127, no. 7, pp. 1201-1213 . https://doi.org/10.1038/s41416-022-01888-2
Grand Challenge PRECISION consortium 2022, ' Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk ', British Journal of Cancer, vol. 127, no. 7, pp. 1201-1213 . https://doi.org/10.1038/s41416-022-01888-2
Background Ductal carcinoma in situ (DCIS) is treated to prevent subsequent ipsilateral invasive breast cancer (iIBC). However, many DCIS lesions will never become invasive. To prevent overtreatment, we need to distinguish harmless from potentially h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbaf3af1076b54e78662cd1902b1bde6
https://research.vumc.nl/en/publications/9cd9c8eb-4ba5-491a-8815-1aa6b8db618c
https://research.vumc.nl/en/publications/9cd9c8eb-4ba5-491a-8815-1aa6b8db618c
Autor:
Maria Roman Escorza, Michael Sheinman, Tycho Bismeijer, Ahmed A. Ahmed, Vandna Shah, Jeffrey R. Marks, Lorraine M. King, Anargyros Megalios, Lindy L. Visser, Marlous Hoogstrat, Helen R. Davies, Tapsi Kumar, Deborah Collyar, Hilary Stobart, Sarah Pinder, Nicholas N. Navin, Andrew Futreal, Serena Nik-Zainal, E. Shelley Hwang, Esther H. Lips, Alastair Thompson, Lodewyk F.A. Wessels, Jelle Wesseling, Elinor J. Sawyer
Publikováno v:
Cancer Prevention Research. 15:PR002-PR002
Introduction: Ductal carcinoma in situ (DCIS) is considered a non-obligate precursor of invasive ductal carcinoma. With the aim of preventing a subsequent invasive cancer, all DCIS lesions are currently treated with surgical excision often supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c1351fc78e27d2f432303d0a2425e5
https://doi.org/10.1158/1940-6215.dcis22-pr002
https://doi.org/10.1158/1940-6215.dcis22-pr002
Autor:
Mathilde M, Almekinders, Tycho, Bismeijer, Tapsi, Kumar, Fei, Yang, Bram, Thijssen, Rianne, van der Linden, Charlotte, van Rooijen, Shiva, Vonk, Baohua, Sun, Edwin R, Parra Cuentas, Ignacio I, Wistuba, Savitri, Krishnamurthy, Lindy L, Visser, Iris M, Seignette, Ingrid, Hofland, Joyce, Sanders, Annegien, Broeks, Jason K, Love, Brian, Menegaz, Lodewyk, Wessels, Alastair M, Thompson, Karin E, de Visser, Erik, Hooijberg, Esther, Lips, Andrew, Futreal, Jelle, Wesseling
Publikováno v:
British journal of cancer. 127(7)
Ductal carcinoma in situ (DCIS) is treated to prevent subsequent ipsilateral invasive breast cancer (iIBC). However, many DCIS lesions will never become invasive. To prevent overtreatment, we need to distinguish harmless from potentially hazardous DC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee2c8544327a38ccc8865101644c501f
https://pubmed.ncbi.nlm.nih.gov/35768550
https://pubmed.ncbi.nlm.nih.gov/35768550